Pharmacodynamics, pharmacokinetics and safety of <scp>GSK</scp>2190915, a novel oral anti‐inflammatory 5‐lipoxygenase‐activating protein inhibitor

Abstract

GSK2190915 is well-tolerated with pharmacokinetics and pharmacodynamics in Western European and Japanese subjects that support once daily dosing for 24 h inhibition of leukotrienes. Doses of ≥50 mg show near complete inhibition of urinary leukotriene E₄ at 24 h post-dose, whereas doses of ≥150 mg are required for 24 h inhibition of blood LTB₄.